Comparative evaluation of cancer stem cell markers in normal pancreas and pancreatic ductal adenocarcinoma

BARBARA VIZIO1, FRANCESCO A. MAURI2, ADRIANA PRATI1, PRITESH TRIVEDI2, ALICE GIACOBINO3, ANNA NOVARINO2, MARIA ANTONIETTA SATOLLI3, LIBERO CIUFFREDA3, MICHELE CAMANDONA1, GUIDO GASPARRI1 and GRAZIELLA BELLONE1

1Department of Clinical Physiopathology, University of Turin, Turin, Italy; 2Department of Histopathology, Hammersmith Hospital, London, UK; 3Department of Medical Oncology, Azienda Ospedaliera Universitaria San Giovanni Battista, Molinette, Turin, Italy

Received February 23, 2011; Accepted April 20, 2011

DOI: 10.3892/or.2011.1461

Abstract. Chemoresistance and self-renewal of cancer stem cells (CSC), found in many tumors including pancreatic ductal adenocarcinoma (PDAC), are believed to underlie tumor mass regrowth. The distribution of cells carrying the putative stem-cell markers CD133, Nestin, Notch1-4, Jagged1 and 2, ABCG2 and aldehyde dehydrogenase (ALDH1) was assessed immunohistochemically using PDAC and normal pancreas tissue microarrays. The immunoreactivity was semi-quantitatively graded against the normal pancreas and was correlated with the differentiation grade and disease stage. No statistical significant differences were found between normal pancreas and PDAC in the expression of Nestin, Notch1, 3 and 4, ABCG2 or ALDH1. Notch2 and Jagged1 and 2 expression were increased in PDAC. CD133-positive cells were above-normal in PDAC, but the difference was not statistically significant. Nestin, Notch1-4, Jagged1, ABCG2 and ALDH1 immunostaining scores were not correlated with tumor grade or disease stage. CD133 and Notch2 expression was significantly inversely correlated with tumor grade, but not disease stage. Notch3 immunostaining positively correlated with tumor stage, but not with differentiation grade. Jagged2 protein expression correlated inversely with disease stage, but not with tumor grade. From the clinical standpoint, improved delineation of the tumor CSC signature, putatively responsible for tumor initiation and recurrence after initial response to chemotherapy, may offer novel therapeutic targets for this highly lethal cancer.

Introduction

One of the major challenges in the treatment of pancreatic ductal adenocarcinoma (PDAC) is the frequent failure of chemotherapy (1). Poor response rates and short progression-free intervals suggest that pancreatic cancer rapidly develops chemoresistance, or possesses it intrinsically. The lack of success with existing strategies underscores the importance of continued research efforts, in the hope of developing novel therapeutic strategies for the treatment of patients diagnosed with PDAC.

The cancer stem cell (CSC) theory (2) has given rise to a paradigm shift in how cancer biologists think about solid organ tumors. Underlying this increasingly-accepted concept is the hypothesis that, just as in organs and tissues, normal stem cells are at the apex of the hierarchical scheme that drives organogenesis, likewise cancer cells possessing the properties of stem cells may be key drivers of the complex machinery underlying tumorigenesis, since tumors themselves may function as complex organs.

Emerging data have shown that tumors are quite heterogeneous, and that they are composed of a small subset of distinct cancer cells, i.e. CSC, which are responsible for tumor initiation and propagation. These CSC, like their normal counterparts, possess the ability to self-renew, to produce differentiated progeny and, most notably, to recapitulate the phenotype of the tumor from which they were derived (12,13).

In normal adult tissues, proper homeostatic tissue maintenance of stem cells is dependent on the integration of both
cell-intrinsic and cell-extrinsic factors, and is achieved by the maintenance of a delicate balance between self-renewal and differentiation. The stem-cell niche has been envisaged to be a physiological microenvironment consisting of specialized cells that physically anchor the stem cell and provide the necessary factors to maintain its stemness (14). In light of the significant role played by the normal stem-cell niche in determining the cells’ fate, it has been proposed that a CSC niche exists and that interactions with this tumor niche may play a similar role in specifying a self-renewing population of tumor cells.

Considerable effort is being expended in the search for markers of stem cells: collectively, these marker molecules appear to be involved in maintaining stemness, and in ensuring adhesion to the stem-cell niche; they may also be involved in cytoprotection (15). The phenotypic characterization of CSC is still debated. CD133, Nestin, Notch1-4, Jagged 1 and 2, ABCG2 and aldehyde dehydrogenase (ALDH1) are recognized as biomarkers that represent the stemness phenotype.

Since the feasibility of targeting the CSC niche therapeutically will at least in part depend on the degree of similarity between normal and CSC niches, the study used immunohistochemical methods to characterize the tissue distribution of these proteins, in formalin-fixed, paraffin-embedded human PDCA tissue, and to compare the findings with the distribution in normal human pancreas.

Materials and methods

PDAC tissue microarrays. Tumor specimens from 37 PDAC patients plus 6 samples of normal pancreatic tissue were analyzed. PDAC tissue microarrays (TMA) were obtained from Pantomics, (Richmond, CA) (duplicate cores per case: 20 cases of ductal adenocarcinoma and 3 cases of normal pancreatic tissue) and from US Biomax (Rockville, MD) (triplicate cores per case, 17 cases of ductal adenocarcinoma and 3 cases of normal pancreatic tissue). Patient characteristics are summarized in Table I. Tissues were fixed in formalin and embedded in paraffin. TMA were validated by hematoxylin and eosin staining.

Immunohistochemistry. Tissue fragments were melted into the acceptor paraffin block by heating the block for 30 min at 60°C. Samples were deparaffinized in xylene and rehydrated in a graded series of alcohols; the antigen was then retrieved in Tris/EDTA buffer (10 mmol/l Tris Base, 1 mmol/l EDTA, pH 9.0) using a pressure cooker. The sections were treated with a 3% solution of H$_2$O$_2$ for 5 min to inhibit endogenous peroxidase activity. After 1 h pre-incubation in a blocking buffer (5% normal goat serum in phosphate-buffered saline) to prevent non-specific staining, the sections were incubated with primary antibodies (Table II), for 45 min. The sections were then treated with the appropriate biotinylated secondary antibodies, followed by incubation with an avidin-biotin peroxidase complex solution, for 30 min, and diaminobenzidine tetrahydrochloride as a chromogen. The slides were finally counterstained with Mayer's hematoxylin for 5 sec, dehydrated, and mounted in Clarion (Biomed, Foster City, CA, USA).

Analysis of immunohistochemical expression patterns. The staining intensity was evaluated by a semi-quantitative method using the immunoreacting score (IRS) proposed by Remmele and Stegner (16) in which IRS = SI (staining intensity) x PP (% of positive cells). SI was assigned as: 0, negative; 1, weak; 2, moderate; 3, strong. PP was assigned as: 0, negative; 1, 1-20% positive cells; 2, 21-50% positive cells; 3, 51-100% positive cells. Ten visual fields from different areas of each specimen were chosen at random for IRS evaluation, and the scores were averaged.

Statistical analysis. All results are expressed as median and range. The immunostaining scores of different stem cell markers in pancreatic carcinoma were compared with the scores in normal pancreas. Statistical analysis was performed using the non-parametric Mann-Whitney test to compare variables. The correlation between different parameters was analyzed using the non-parametric Spearman correlation coefficient; p-values of <0.05 were considered to indicate statistical significance. All statistical analyses were performed using the SigmaStat software (Jandel Scientific, San Rafael, CA, USA).

Results

Distribution of CD133, Nestin, Notch (1-4), Jagged1 and 2, ABCG2 and ALDH1 in normal pancreas and PDAC. The distributions of CD133, Nestin, Notch (1-4), Jagged 1 and 2, ABCG2 and ALDH1 are summarized in Tables III and IV; representative staining profiles are in Fig. 1.

CD133. Immunoreactivity was observed in the center of the normal acini and in neoplastic ductal structures in a basilar pattern, defined by staining at the apical membrane of the cells. Staining was not seen in any specimen in the islets of Langerhans. Immunoreactivity to CD133 was retained in 29.7% (11/37) cases of PDCA, while expression was lost in 70.3% of cases (26/37). In the positive cases, the area and intensity of expression varied along with the morphological heterogeneity of the tumor. No statistically-significant

<table>
<thead>
<tr>
<th>Table I. Clinical characteristics of the patients.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pancreas ductal adenocarcinoma, N</td>
</tr>
<tr>
<td>Gender (male/female)</td>
</tr>
<tr>
<td>Age (median, range)</td>
</tr>
<tr>
<td>Histological grading, N</td>
</tr>
<tr>
<td>Well-differentiated (G1)</td>
</tr>
<tr>
<td>Moderately differentiated (G2)</td>
</tr>
<tr>
<td>Poorly differentiated (G3)</td>
</tr>
<tr>
<td>Stage (UICC staging system), N</td>
</tr>
<tr>
<td>I</td>
</tr>
<tr>
<td>II</td>
</tr>
<tr>
<td>III</td>
</tr>
<tr>
<td>IV</td>
</tr>
<tr>
<td>Normal pancreas, N</td>
</tr>
<tr>
<td>Gender (male/female)</td>
</tr>
<tr>
<td>Age (median, range)</td>
</tr>
</tbody>
</table>
Table II. Antibodies used in immunohistochemistry.

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Antibody species</th>
<th>Manufacturer</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD133/1</td>
<td>Mouse monoclonal</td>
<td>Miltenyi BioTec, Bergisch Gladbach, Germany</td>
<td>1:50</td>
</tr>
<tr>
<td>Nestin</td>
<td>Mouse monoclonal</td>
<td>Santa Cruz Biotechnology, Santa Cruz, CA</td>
<td>1:50</td>
</tr>
<tr>
<td>Notch1</td>
<td>Goat polyclonal</td>
<td>Santa Cruz Biotechnology</td>
<td>1:100</td>
</tr>
<tr>
<td>Notch2</td>
<td>Rabbit polyclonal</td>
<td>Santa Cruz Biotechnology</td>
<td>1:100</td>
</tr>
<tr>
<td>Notch3</td>
<td>Rabbit polyclonal</td>
<td>Santa Cruz Biotechnology</td>
<td>1:100</td>
</tr>
<tr>
<td>Notch4</td>
<td>Rabbit polyclonal</td>
<td>Santa Cruz Biotechnology</td>
<td>1:100</td>
</tr>
<tr>
<td>Jagged1</td>
<td>Goat polyclonal</td>
<td>Santa Cruz Biotechnology</td>
<td>1:100</td>
</tr>
<tr>
<td>Jagged2</td>
<td>Rabbit polyclonal</td>
<td>Santa Cruz Biotechnology</td>
<td>1:100</td>
</tr>
<tr>
<td>ABCG2</td>
<td>Mouse monoclonal</td>
<td>Chemicon International, Temecula, CA</td>
<td>1:30</td>
</tr>
<tr>
<td>ALDH1</td>
<td>Rabbit monoclonal</td>
<td>Abgent, San Diego, CA</td>
<td>1:25</td>
</tr>
</tbody>
</table>

Figure 1. Differential expression of Nestin, Notch2, Jagged1 and Jagged2 proteins in normal pancreas and pancreatic ductal adenocarcinoma (PDAC) tissue specimens as determined by immunohistochemistry. Specimens are representative examples of 6 non-tumoral and 37 tumoral pancreas tissue samples (original magnification, x250).
difference was detected in the IRS between the normal pancreas and positive PDAC [median (range): 1 (1-2) vs. 1 (0.5-3), p=0.186].

**Notch1.** In normal pancreas, positive cells were identified in the acini and also in the cells of the islets of Langerhans. Notch1 expression was identified in 94.6% of PDAC specimens (35/37). Immunostaining was observed in the cytoplasm of neoplastic ductal structures. No statistically-significant difference was detected in IRS between normal pancreas and PDAC; median (range): 3 (0-4) vs. 3 (0-9), p=0.186).

**Notch2.** No immunostaining was seen in normal pancreas (acinar cells nor islets of Langerhans). Notch2 expression in PDAC was identified in 51.3% of specimens (19/37). Immunostaining was observed in the cytoplasm of non-neoplastic exocrine pancreas adjacent to ductal adenocarcinoma cells.

**Notch3.** In the normal pancreas, Notch3 expression was identified in the cytoplasm of cells of the islets of Langerhans and acinar cells, with immunostaining intensity being stronger in the latter. Notch3 expression was found in 37.8% of specimens (14/37). Cytoplasmic and nuclear immunostaining was identified in neoplastic ductal structures. No significant differences in IRS between normal and tumor pancreas (median (range) 0 (0-0.667) vs. 0.5 (0-1.5), p=0.385).

**Notch4.** In normal pancreas, Notch4-positive cells were only identified in the cells of the islets of Langerhans. No positive acinar cells were seen. Expression was not identified in any PDAC specimens.

**Jagged1.** In normal pancreas, Jagged1-positive cells were focally identified in the acini, whereas cells of the islets of
Langerhans were negative. Expression was identified in 40.5% of PDAC specimens (15/37). Immunostaining was observed in the cytoplasm of neoplastic ductal structures. A statistically-significant increase in IRS was found in positive PDAC vs. normal pancreas. The median (range) was 0.750 (0-3.7) in PDAC vs. 0 (0-1) in normal (p=0.040).

Jagged2. In normal pancreas, immunostaining for Jagged2 was negative in both exocrine and endocrine components. Expression was identified in 67.6% of PDAC specimens (25/37). Immunostaining was observed in the cytoplasm of neoplastic ductal structures. Interestingly, acinar cells were positive in non-neoplastic exocrine pancreas adjacent to ductal adenocarcinoma cells; IRS median range: 1 (0-6).

ABCG2. Weak cytoplasmic staining was focally seen in the acinar cells of the normal pancreas. Occasional ABCG2-positive cells were identified in 5.4% of PDAC specimens (2/37). Immunostaining was identified in the tumor-cell cytoplasm. Normal endocrine islets were negative. Similar IRS values were observed between normal and PDAC specimens; median (range): 0 (0-0.33) vs. 0 (0-1), p=0.919.

ALDH1. In normal pancreas, ALDH1-positive cells were focally identified in the acini. Expression was identified in 29.7% of PDAC specimens. Immunostaining was observed in the cytoplasm of neoplastic ductal structures. Cells of the islets of Langerhans were also positive, particularly in the areas containing β-cells (insulin production). No significant differences were found between normal and positive tumor pancreas specimens; median (range): 1.5 (1-3) vs. 1 (0-4), p=0.125.

Correlation among stem cell marker expression, differentiation grading and disease staging. The correlation among IRS of different stem cell markers expressed in tumor tissues, differentiation grading, and disease staging, was calculated by the Spearman rank order correlation test (Table IV). CD133 protein expression was inversely and significantly correlated with tumor differentiation grading (p=0.03), but not with tumor stage (p=0.545). Notch1, Notch4, Jagged1, ABCG2 and ALDH1 IRS were not associated with either tumor differentiation grade (p=0.999, p=0.937, p=0.120, p=0.308, p=0.143, respectively) or tumor stage (p=0.786, p=0.384, p=0.102, p=0.380, p=0.090, respectively). Notch2 protein expression was positively correlated with differentiation grade (p=0.003), but not with tumor stage (p=0.521). A positive correlation was found between Notch3 immunostaining and tumor stage (p=0.023), but not with differentiation grade (p=0.544). By contrast, Jagged2 protein expression was inversely correlated with tumor stage (p=0.005), but was not correlated with tumor differentiation grade (p=0.950).

Discussion

It has recently been reported that, in addition to initiating and sustaining tumor growth, CSC may also mediate cancer drug resistance, relapse and metastasis; this has been found to occur in several human malignancies, including PDAC. Nevertheless, little is known about the expression of CSC markers in situ, especially in relation with normal pancreas and the tumor's grade of malignancy. To address this problem, we investigated the concomitant expression of ten proteins: CD133, Nestin, Notch1, Notch2, Notch3, Notch4, Jagged1, Jagged2, ABCG2 and ALDH1, which are the most widely-accredited markers for identification of CSC.

The expression of CD133 (human prominin-1), originally identified as a cell-surface antigen present in CD34+ hematopoietic stem cells, is one criterion which has been used to identify putative CSC in solid tumors, such as brain (6,17), lung (18), skin, melanoma (19), prostate (10), kidney (20) colon (7,8) and liver (21).

In our series of cases, CD133 expression was increased in PDAC vs. normal pancreatic epithelial cells, although statistical significance was not achieved. Moreover, we found this marker to be inversely associated with tumor differentiation grade, in line with studies reporting both the presence of CD133 in different types of stem cells and in several solid tumors, and its down-regulated expression in differentiated cells (22). In particular, it has been demonstrated that CD133 is a marker of putative pancreatic progenitor cells during embryogenesis (23). The localization of the CD133 marker on the apical cell surface, in both normal and tumor tissues, suggests its involvement in the mechanisms influencing cell polarity, migration and interaction of stem cells with neighboring cells and/or the extracellular matrix, although experimental data are not yet available. Side populations of cells with stem-cell characteristics, isolated from human pancreatic carcinoma cells, show significantly higher levels of mRNA expression for CD133 and have high resistance to gemcitabine treatment, a chemotherapeutic drug currently used in clinical settings against aggressive PDAC (24).

Nestin, originally described as a neuronal stem cell/progenitor cell marker during central nervous system development (25,26), was initially described in the adult pancreas as a specific marker of a cell subpopulation having a possible stem-cell function (27).

In agreement with other reports (28,29), the immunohistochemical studies to characterize Nestin expression in the normal pancreas and in PDAC showed that Nestin was localized in a few capillary endothelial cells and nerve fibers within the islets of normal pancreatic tissues and in numerous capillary endothelial cells and nerve fibers invading the tumor area in PDAC. Despite the Nestin cellular localization revealed by immunohistochemistry, lineage-tracing experiments indicate that the cells derived from Nestin-expressing progenitor cells are mostly exocrine cells (30,31). Moreover, in rodents, Nestin-expressing cells contribute to the regenerative capacity of the exocrine pancreas, after partial pancreatectomy and during recovery from acute pancreatitis (32). In a mouse model, it has been demonstrated that activation of oncogenic K-ras in the Nestin cell lineage is sufficient to initiate pancreatic intraepithelial neoplasia lesions (PanINs), putative precursors to PDAC (33), suggesting that these cells may be the elusive progenitor population from among which PDAC arises.

During development of the pancreas, differentiation of epithelial precursors is tightly regulated by Notch signaling, a highly conserved pathway known to regulate cell-fate decisions in a variety of organisms (34). In vertebrates there are four Notch transmembrane receptors, Notch 1, 2, 3 and 4, whose activities are controlled by the family ligands, Delta-like and Jagged (Jagged1 and Jagged2) (35). Moreover, mechanistically,
increased Notch signaling is associated with chemoresistance, and with the epithelial-mesenchymal transition (EMT) characteristic of pancreatic carcinoma cells (36).

Among the four members of the Notch protein family, we found that Notch1 and Notch4 were similarly expressed in normal and tumor tissues, and were not correlated to either tumor differentiation grade or stage. Interestingly, though, cytoplasmic Notch2 expression was identified in approximately 50% of PDAC cells, but not in their normal counterparts, and there was a positive correlation with the grade of tumor differentiation. It has been reported that immortalized human pancreatic Nestin-expressing cells, after transfection with cDNA of the catalytic subunit of telomerase (hTERT-HPNE), have properties identical to those of the intermediary cells observed during acinar-to-ductal metaplasia (37), and that unlike their native counterparts they express Notch2 (38). By contrast, Notch3 protein was not differentially expressed in quantitative terms in PDAC vs. normal pancreas. However, in tumors, its expression was correlated with disease stage, suggesting that Notch3 is mechanistically linked with a more malignant phenotype.

Notch signaling is activated through the interaction of Notch receptors with Delta-like and Jagged ligands on neighboring cells (39). It consists of two cleavages, occurring at the extracellular side, followed by a third cleavage that liberates the intracellular Notch receptor domain, which is translocated to the cell nucleus (40,41), where it regulates the balance between cell differentiation and stem cell proliferation, during the development of numerous tissues, including the pancreas (34,42). It is likely that this latter form participates in neoplastic cell transformation in several organs, such as the cervix, uteri, lung, breast, nerve tissue and also in the pancreas (43-47). However, the cases of staining in PDAC that we found were uniformly cytoplasmic, with no nuclear Notch2 and Notch3 being observed in any case; it is thus likely that tumors expressing nuclear Notch2 and Notch3 had been found to be non-transportable.

We found that both Jagged1 and Jagged2 ligands were more strongly expressed in tumor lesions that in normal tissue counterparts. In our series of tissues, Notch2 and Notch3 receptors were up-regulated in the tumor specimens. Thus, Notch can be reactivated in pancreatic tumors and may potentially be linked to stemness acquisition and to EMT (36).

CSC have been hypothesized to be resistant to conventional chemotherapy and radiation therapy, and are thought to be the culprits behind cancer metastasis and recurrence after clinical remission. The ABC transporter family ABCG2 functions as a high-capacity drug transporter with wide substrate specificity (48). Expression of ABCG2 is observed not only in adult stem cells but also in primary cancer cells and cell lines, where it confers a multidrug resistant phenotype, although its precise physiological role in stem cells is still unclear (49). In our study, we identified ABCG2-positive cells only occasionally and in only a few PDAC patients, with IRS values similar to those of normal pancreas, in agreement with what has been reported by König et al (50).

ALDH1 is part of a group of NAD(P)^+ -dependent enzymes involved in oxidizing a wide variety of aldehydes into their corresponding carboxylic acids (51). ALDH1 activity identifies normal stem cells and tumor-initiating cells (i.e. CSC) in several human malignancies, where it seems to play an important role in drug resistance, cell proliferation, differentiation and response to oxidative stress (52-54). It is reported that ALDH1 is required for development of the pancreas during mouse embryogenesis, and is associated with tumorigenic pancreatic cancer cells both in vitro and in vivo. We found that the majority of primary tumor specimens lacked expression of ALDH1-positive cells (70%), while this protein was widely expressed in normal pancreas specimens. This is in contrast with a recent study (55) that found high expression of ALDH1 in PDCA. This discrepancy might be due to variability in tumor sampling, or it could be that tumors are phenotypically and functionally distinct in terms of CSC.

Although an optimal enumeration technique has not yet been determined, and consensus has not yet been reached concerning the phenotypic definition of CSC, clinical studies assessing these cells in cancer patients are increasingly being reported. However, inter-laboratory variability, resulting from doubt over the definition of CSC, and different technical methods (e.g., antigen retrieval and detection methods) used in the different studies, make comparison among different reports difficult.

It is clear that additional research is needed to increase our understanding of the molecular machinery underlying the regulation of cell self-renewal and resistance to chemotherapy and radiation in pancreatic CSC, and that much is yet to be learned about the intricacies of the pancreatic cancer microenvironment and its causes. However, our study points to a possible different pattern of frequency and localization of CSC markers in PDAC vs. normal pancreas, in particular concerning the Notch pathway and Jagged ligands. Improved delineation of such a signature would be very important to develop targeted combination therapies for selective elimination of CSC, having minimal toxicity to normal stem cells, which would likely benefit patients suffering from this difficult to treat disease.

Acknowledgements

This study was supported by grants from the Piedmontese Regional Government to G.B.

References


Jing N: Mouse nestin cDNA cloning and protein expression in pancreatic progenitor cells from mice by sorting for prominin1 (CD133) and platelet-derived growth factor receptor beta. Stem Cells 23: 791-804, 2005.


Lee KM, Yasuda H, Hollingsworth MA and Ovesenette MM: Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest 85: 1003-1012, 2005.


